Skip to content

Trial · Interventional

CompletedPhase 1Registry data

Pharmacological Approach to Improve the Outcome of Social Cognition Training

Overview

Status
Completed
Phase
Phase 1
Enrollment
27 participants (actual)
Sponsor
VA Greater Los Angeles Healthcare System · Fed
Design
Randomized · Quadruple masking
Countries
1 country

United States

Start
Jan 2012
Primary completion
Feb 2013
Completion
Feb 2013
First posted
25 Jan 2012 (estimated)
Last update posted
29 Mar 2013 (estimated)
Conditions
Schizophrenia

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201220132014
  1. Ph 1

    Pharmacological Approach to Improve the Outcome of Social Cognition Training

    NCT01517360

    Jan 2012 to Feb 2013

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST). The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of SCST.

Interventions

  • OxytocinDrug
  • PlaceboOther
  • Social Cognitive Skills TrainingBehavioral

Arms2

  • Active comparator

    Placebo+Social Cognitive Skills Training

    The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).

  • Experimental

    Oxytocin+Social Cognitive Skill Training

    The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Composite Social Cognition Score

    Time frame · Baseline, 6 weeks, and 10 weeks

    Registry description

    We will assess emotion management, emotion perception, social context processing/social perception, theory of mind, attributional bias, and empathic accuracy. The primary summary measure for each test will be mean-centered and standardized to create a Z-score that will be averaged to create a single composite score for social cognition, serving as the primary outcome measure. Parallel follow-up analyses will be conducted on individual components to determine which measures are most affected by treatment. Similar secondary analyses will be employed for the event related potential (ERP) and basic cognition measures.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2010

4 results

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

Feifel et al. 2010Biological psychiatrycited by 243

PMID 20615494DOI 10.1016/j.biopsych.2010.04.039PUB-20615494

Full text at the publisher4 results

More studies

1 study on this page

Indexing hint: Review · 2009

Oxytocin, vasopressin, and human social behavior.

Heinrichs et al. 2009Frontiers in neuroendocrinologycited by 559

PMID 19505497DOI 10.1016/j.yfrne.2009.05.005PUB-19505497

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
Male
Age
from 18 Years up to 55 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition * Stable on an antipsychotic medication * No change in antipsychotic dose of \>10% during the past 3 months Exclusion Criteria: * Unable to provide informed consent * History of epilepsy * Active medical conditions that would make the study unsafe * History of serious head injury * History of hyponatremia

PepBank is a research reference. Talk to a doctor before you use any peptide.